Dyadic International's total revenue for Q1 2014 up 20%

Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and others proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, today announced financial results for the first quarter ended March 31, 2014.

Chief Executive Officer, Mark Emalfarb, stated, "Dyadic is off to a strong start in 2014. Investments in our proprietary technologies are continuing to pay off on multiple fronts.  Revenues grew 20% in the first quarter. This is a result of increased sales in all of our targeted market sectors, including animal nutrition, starch, alcohol and brewing. Our gross profit has nearly doubled, led by progress made on both the product and R&D side of the business.  Enzyme product margins are improving due to a combination of positive factors, including decreased raw material costs and improved productivity gains. We are also very proud to announce that the expansion of our Dutch research center is already starting to produce better than expected results with both internal and external research projects.  Earlier this week, we announced the strengthening of our management team in Europe. The hiring of a Vice President of Business Development and Director of Sales will allow the Dyadic team to tap into the extensive experience each of them brings from within the biotechnology industry.  Also accomplished in the first quarter, we uplisted our stock to the OTCQX marketplace, providing our shareholders with greater transparency. Dyadic's technology licensing model is expected to bring us recurring royalty streams in a broad variety of end markets.  We anticipate the first of such royalties later this year from Abengoa Bioenergy, a C1 licensee.  Abengoa has reported that their cellulosic ethanol plant in Hugoton, Kansas will begin operations this year. By strengthening our European leadership team and expanding our Dutch research center we expect to see more rapid technology advancements and accelerated growth in research and product revenues. We are committed to augmenting our leadership team worldwide, and we look forward to making additional announcements in the coming months."

Q1 2014 Financial Results

Revenue

Total revenue increased 20% for the three months ended March 31, 2014 to $3.0 million as compared to $2.5 million for the prior year.

Net product related revenue increased over 17% to $2.5 million for the three months ended March 31, 2014, as compared to $2.1 million for the prior year.  This increase was due both to several new customers in certain key markets, including animal feed, starch, alcohol and brewing, and increased sales to existing customers.   

Research and development revenue for the quarter increased 36% to $526,000 compared to $387,000 for the same period in 2013.  The increase was due to the start of certain external research and development projects and better than expected performance by our team of scientists on executing those projects ahead of schedule. 

There was no license fee revenue recorded in the first quarter of 2014.

Cost of Goods Sold

For the three months ended March 31, 2014, cost of goods sold was approximately $2.0 million, or 66% of total revenue, as compared to approximately $2.0 million, or 79% of total revenue for the three months ended March 31, 2013.  The decrease in cost of goods sold as a percentage of total revenues was primarily the result of improved product related margins and very efficient project execution on research and development revenue generating projects, which in the aggregate, accounted for the improvements.

Gross Profit

Gross profit increased from $520,000 in the first quarter of 2013 to $1,000,000 in the first quarter of this year. Gross profit margins increased from 21% last year to 34% for the first quarter of 2014.  Margins improved in both product related revenues and research and development revenues. The margin increases in product related revenues were due in part to reduced raw material costs and increased productivity due to modified fermentation and downstream processing equipment. Additionally, price increases on certain higher volume products contributed to the increase in gross profit.  Our margins on research and development revenues were up as we reached certain project objectives on in our research program earlier than expected that allowed us to recognize revenues with higher margins. 

General and Administrative

Total general and administrative expenses for the quarter increased 51% to $1.9 million compared to $1.3 million for the same period in 2013.  The increase was due primarily to expert costs associated with the ongoing litigation against the Company's former outside legal counsel of approximately $675,000, as compared to $185,000 in Q1 of 2013.  Excluding legal fees associated with the lawsuit, general and administrative expenses were up 14% from the prior year. Costs and expenses related to the lawsuit are expected to decrease significantly through the remainder of the 2014.  The professional liability lawsuit is expected to continue through 2014, with an anticipated trial date sometime in 2015. Costs and expenses will again increase as we near trial preparation, and throughout the trial itself. 

Sales and Marketing

Sales and Marketing costs increased $37,000, or 18% quarter over quarter.  The majority of the increase was due to additional sales resources brought online in the second quarter of 2013.  As we recently announced, we added sales resources starting in June 2014 and expect to continue to expand the team during the remainder of 2014.

Research and Development       

Research and development expense increased 14% to $330,000.  This increase is lower than anticipated as technical resources were deployed on certain third party funded projects during the quarter.  It is expected that research and development spending will increase through the remainder of the year.

Gain on Sale of Fixed Assets

During the first quarter of 2014, as previously announced, we closed our Greensboro, North Carolina facility and sold the assets for a net gain of approximately $12,000.  We do not anticipate any further costs associated with the closure.

Net Loss

Net loss for the three months ended March 31, 2014 was $1.6 million, or ($0.05) per basic and fully diluted share, as compared to a net loss of $1.5 million, or ($0.05) per basic and fully diluted share, for three months ended March 31, 2013. Exclusive of litigation related legal fees, the net loss for the three months ended March 31, 2014 would have been $894,000, or ($0.03) per basic and fully diluted share, as compared to a net loss of $1.3 million, or ($0.04) per basic and fully diluted share, for the three months ended March 31, 2013.

Cash and Cash Equivalents

At March 31, 2014, cash and cash equivalents totaled $7.0 million as compared to $8.9 million at December 31, 2013. The decrease was substantially due to the increase in legal expenses and inventory on hand to satisfy anticipated sales for 2014.  Additionally, Dyadic launched its new Fibrezyme G4 product in April, which required cash expenditures to ensure product availability in certain strategic geographic regions to meet projected demand.

Debt

Total Convertible Subordinated Debt ("Debt") as of March 31, 2014 was $6.8 million. On October 1, 2013, the Company extended the maturity dates of all of its outstanding debt to January 1, 2015. The Company has the right to prepay all of the debt any time after March 31, 2014, without penalty, with 30 days written notice. The remaining $1.4 million Note Payable to Stockholder is non-convertible, and is not subject to the prepayment provision.  All debt is classified as short-term in the Condensed Consolidated Balance Sheet as of March 31, 2014.

Capital expenditures for the three months ended March 31, 2014 were approximately $84,000 as compared to $88,000 for the same period last year.

Cash Flow From Operating Activities

As reflected in our condensed consolidated financial statements, we incurred a loss of approximately $1.6 million and $1.5 million for the three months ended March 31, 2014 and 2013, respectively.  Net cash used in operating activities was approximately $1.8 million in the first quarter of 2014 as compared to $153,000 provided by operations in the first quarter of 2013.  The majority of the cash used in operating activities in the first quarter of 2014 was related to the increase in litigation related legal expenses and increased inventory levels previously mentioned. The first quarter of 2013 included $1,000,000 cash received as part of the Abengoa license expansion in 2012.

From Investing Activities

For the three months ended March 31, 2014, our net cash used in investing activities was approximately $65,000 as compared to approximately $90,000 for the three months ended March 31, 2013. The decrease is mainly due to the completion of our facility expansion at our Dutch research center in late 2013 and early 2014 in support of our new product development initiatives.

From Financing Activities

For the three months ended March 31, 2014, there was no net cash provided by financing activities. Approximately $59,000 was raised during the three months ended March 31, 2013. This amount is primarily due to cash received from proceeds from the exercises stock options, granted under our equity plans.

The financial information contained in this earnings press release should be read in conjunction with the financial statements and related footnotes which have been posted on the OTC marketplace website at www.otcmarkets.com/stock/DYAI/filings and on Dyadic's website at www.dyadic.com/investorinfo/financials/.

Source:

Dyadic International, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Why do we blush, and what are the underlying mechanisms of blushing? Research aims to find out